REPL
Replimune Group Inc
NASDAQ · Biotechnology
$7.75
+0.82 (+11.83%)
Open$7.14
Previous Close$6.93
Day High$7.80
Day Low$7.12
52W High$14.80
52W Low$2.68
Volume—
Avg Volume1.17M
Market Cap639.94M
P/E Ratio—
EPS$-3.46
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+358.7% upside
Current
$7.75
$7.75
Target
$35.55
$35.55
$27.68
$35.55 avg
$47.36
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.24M | 87.45M | 85.26M |
| Net Income | -25,675,790 | -26,182,971 | -21,946,443 |
| Profit Margin | -28.5% | -29.9% | -25.7% |
| EBITDA | -28,181,466 | -22,488,865 | -22,555,214 |
| Free Cash Flow | -17,519,035 | -21,453,021 | -16,827,154 |
| Rev Growth | -3.7% | +3.8% | +9.6% |
| Debt/Equity | 1.03 | 0.84 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |